Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. Financials
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
Delayed Quote. Delayed Nasdaq - 09/17 04:00:00 pm
359.18 USD   -3.61%
09/18PRESS RELEASE : FDA Advisory Committee Votes -4-
DJ
09/18PRESS RELEASE : FDA Advisory Committee Votes -3-
DJ
09/18PRESS RELEASE : FDA Advisory Committee Votes -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization1 6 83716 07173 987--
Entreprise Value (EV)2 6 31814 96464 88753 82647 481
P/E ratio -35,6x1 112x8,64x8,08x14,6x
Yield -----
Capitalization / Revenue 63,0x33,3x4,39x4,26x6,89x
EV / Revenue 58,2x31,0x3,85x3,10x4,42x
EV / EBITDA -42,8x-343x4,98x4,46x5,99x
Price to Book 13,9x11,8x6,84x4,02x3,28x
Nbr of stocks (in thousands) 226 262240 786241 521--
Reference price (EUR) 30,266,7306306306
Announcement Date 03/31/202003/30/2021---
1 USD in Million
2 EUR in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023
Net sales1 10948216 86317 34910 735
EBITDA1 -148-43,713 02412 0637 924
Operating profit (EBIT)1 -182-82,413 08013 5228 945
Operating Margin -167%-17,1%77,6%77,9%83,3%
Pre-Tax Profit (EBT)1 -179-14612 77514 90210 963
Net income1 -17915,28 8819 9146 724
Net margin -165%3,15%52,7%57,1%62,6%
EPS2 -0,850,0635,537,920,9
Dividend per Share2 -----
Announcement Date 03/31/202003/30/2021---
1 EUR in Million
2 EUR
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1
Net sales1 3452 0485 3094 8124 4584 833
EBITDA1 2571 6754 2153 0002 343-
Operating profit (EBIT)1 2441 6624 1983 7003 2063 264
Operating Margin 70,7%81,1%79,1%76,9%71,9%67,5%
Pre-Tax Profit (EBT)1 2061 6424 0233 1132 8793 141
Net income1 3671 1282 7872 4092 1232 168
Net margin 106%55,1%52,5%50,1%47,6%44,8%
EPS2 1,574,3910,89,568,6711,3
Dividend per Share ------
Announcement Date 03/30/202105/10/202108/09/2021---
1 EUR in Million
2 EUR
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt1 -----
Net Cash position1 5191 1079 10020 16026 506
Leverage (Debt / EBITDA) 3,52x25,4x-0,70x-1,67x-3,35x
Free Cash Flow1 -237-79,59 5299 7217 842
ROE (Net Profit / Equities) -47,1%1,63%137%50,4%10,1%
Shareholders' equity1 3809336 46919 66666 715
ROA (Net Profit / Asset) -24,7%0,98%112%46,9%7,05%
Assets1 7251 5587 95021 13895 369
Book Value Per Share2 2,185,6844,876,293,3
Cash Flow per Share2 -0,94-0,0548,143,9-1,57
Capex1 38,666,0207115135
Capex / Sales 35,5%13,7%1,23%0,66%1,26%
Announcement Date 03/31/202003/30/2021---
1 EUR in Million
2 EUR
Key data
Capitalization (USD) 86 749 536 126
Net sales (EUR) 482 325 000
Net sales (USD) 565 526 063
Number of employees 2 500
Sales / Employee (EUR) 192 930
Sales / Employee (USD) 226 210
Free-Float 87,3%
Free-Float capitalization (USD) 75 704 351 861
Avg. Exchange 20 sessions (EUR) 1 406 145 198
Avg. Exchange 20 sessions (USD) 1 648 705 244
Average Daily Capital Traded 1,62%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA